Mayer-Rokitansky-Kuster-Hauser syndrome accompanied by invasive ductal carcinoma: a case report

Müllerian agenesis and the absence of organs of Müllerian canal origin are referred to as Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome. Invasive ductal carcinoma constitutes 47-75% of all breast carcinomas and is the most common type. The authors report the first case of invasive ductal carcinoma associated with MRKH syndrome in the literature to their knowledge. A 25-year-old woman with a palpable mass in her right breast for three months presented to the presented clinic. On physical examination a mobile, firm mass measuring 2×2 cm was detected in right breast, at a region close to axilla. A fine needle aspiration biopsy from the lesion revealed malignant cells and thus a segmental mastectomy operation was performed. All genital tract and endocrinological system should be thoroughly examined before administering hormone replacement therapy to patients presenting with primary amenorrhea.The co-occurrence MRKH syndrome of with invasive ductal carcinoma is regarded as coincidental. Confirming the absence of a common etiology, however, requires further genetic studies.

Mayer-Rokitansky-Kuster-Hauser syndrome; Invasive ductal carcinoma; MRI.

[1] Droegemueller W., Herbst A.L., Mishell D.R. Jr., Stenchever M.A.: “Comprehensive gynecology”. 3rded. St. Louis: Mosby, 1997, 294.

[2] Oppelt P., Renner S.P., Kellermann A., Brucker S., Hauser G.A., Ludwig K.S., et al.: “Clinical aspects of Mayer-Rokitansky-Kuster-Hauser syndrome: recommendations for clinical diagnosis and staging”. Hum. Reprod., 2006, 21, 792.

[3] Glass A.G., Lacey J.V., Carreon J.D., Hoover R.N.: “Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status”. J. Natl. Cancer Inst., 2007, 99, 1152.

[4] Chervenak F.A., Stangel J.J., Nemec M., Amin H.K.: “Mayer-Rokitansky- Küster- Hauser syndrome. Congenital absence of vagina”. N.Y. State J. Med., 1982, 82, 23.

[5] Atabek M.E., Pirgon O., Sert A.: “Mayer-Rokitansky-Kuster-Hauser syndrome presenting as premature thelarche in a young child”. Pediatr. Int., 2007, 49, 533.

[6] Orvis G.D., Behringer R.R.: “Cellular mechanisms of Mullerian duct formation in the mouse”. Dev. Biol., 2007, 306, 493.

[7] Bernardini L., Gimelli S., Gervasini C., Carella M., Baban A., Frontino G., et al.: “Recurrent microdeletion at 17q12 as a cause of Mayer– Rokitansky– Kuster–Hauser (MRKH) syndrome: two case reports”. Orphanet. J. Rare Dis., 2009, 4, 25.

[8] Ghirardini G., Magnani A.: “Mayer–Rokitansky–Kuster–Hauser syndrome and ovarian cancer: report of a case.” Clin. Exp. Obstet. Gynecol., 1995, 22, 247.

[9] Fukuda J., Kumazawa Y., Fujimoto T., Tanaka T.: “Mayer-Rokitansky- Kuster-Hauser syndrome complicated by either uterine leiomyoma or ovarian tumor”. J. Obstet. Gynaecol. Res., 2010, 36, 191.

[10] Lacey J.V. Jr., Devesa S.S., Brinton L.A.: “Recent trends in breast cancer incidence and mortality”. Environ. Mol. Mutagen., 2002, 39, 82.

[11] Pike M.C., Spicer D.V., Dahmoush L., Press M.F.: “Estrogens, progesterone, normal breast cell proliferation and breast cancer risk”. Epidemiol. Rev., 1993, 15, 17.

[12] Bernstein L., Ross R.K.: “Endogenous hormones and breast cancer risk”. Epidemiol. Rev., 1993, 15, 48.

[13] Davis D.L., Telang N.T., Osborne M.P., Bradlow H.I.: “Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer”. Environ. Health Perspect., 1997, 105, 571.

[14] McDonnell D.P.: “The molecular pharmacology of SERMs”. Trends Endocrinol. Metab., 1999, 10, 301.